The advancement of antibody discovery technologies like hybridoma, display libraries, Single B-cell sorting/sequencing, and computational modeling has led to the production of thousands of monoclonal antibodies (mAbs). However, identifying the "best-in-class" antibody therapeutics requires rapid assessment using high throughput (HTP) processes.
Recombinant antibodies are monoclonal antibodies produced in vitro through synthetic genes and antibody fragments, instead of using hybridomas. They can take several different formats, such as full-length immunoglobulins (Ig), monovalent antibody fragments such as single-chain fragment variable (scFv) and fragment antigen-binding (Fab), and multimeric diabodies (dimeric scFvs) or triabodies (trimeric scFvs).
A VHH antibody is the antigen binding fragment of heavy chain only antibodies. They are derived from the immune system of camelids such as alpacas. As they are highly stable and much smaller than traditional antibodies, VHH antibodies are ideal for a wide range of applications, including diagnostic tests, therapeutics, and research tools.
High-throughput (HTP) recombinant antibody production is the rapid generation of large numbers of recombinant antibodies. This enables the acceleration of research, paving the way towards clinical trials, as well as streamlining the discovery and development processes.
Biointron’s 2-week high-throughput recombinant antibody production is the leading gene-to-antibody workflow in the industry. By integrating our recombinant protein expression service, we ensure the efficient and scalable production of antibodies tailored to meet diverse research and therapeutic needs. We offer the flexibility to rapidly express large amounts of antibodies at varying scales using HEK293 or CHO cells, which are known for efficient recombinant protein production. As part of this approach, our mammalian protein expression service provides an optimized platform for generating high-quality antibodies with superior functionality.
